NCT00194766View on ClinicalTrials.gov

Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 31, 2000

Study Completion Date

December 31, 2006

Conditions
Breast CancerSoft Tissue Sarcoma
Interventions
DRUG

Temozolomide

Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.

Trial Locations (1)

98109-1023

University of Washington/Seattle Cancer Care Alliance, Seattle

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

University of Washington

OTHER